Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 134Observational 2Expanded_access 1

Sponsor

Cancer Type

Dermatologic 2Genitourinary 1

Conditions

Melanoma 2Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Blood Specimen Collection 14Nivolumab 13Ipilimumab 12pembrolizumab 11trametinib 9Surveys and Questionnaires 9Gene Expression Profiling 9dabrafenib 8Biopsy 6Specimen Handling 5Immunotherapy 5Immunohistochemistry 5Amplified Fragment Length Polymorphism Analysis 4encorafenib 3binimetinib 3atezolizumab 3Restraint, Physical 3Quality of Life 3Polymerase Chain Reaction 3Introns 3Flow Cytometry 3Drug Therapy 3Data Collection 3tremelimumab 2pimonidazole 2cobimetinib 2aldesleukin 2Watchful Waiting 2Vemurafenib 2Therapeutics 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Melanoma × aldesleukin × Clear all
NCT00617799 2023-10-10

Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma

University of Nebraska

Completed
15 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma

NCT01288963 2023-06-15

IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma

Beth Israel Deaconess Medical Center

Completed
153 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡